Source-grounded facts extracted from Anebulo Pharmaceuticals, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Anebulo Pharmaceuticals, Inc.: Conforming amendment to Bylaws related to board declassification (effective 2025-04-11).
“On April 11, 2025, the Company’s Board of Directors approved an amendment (the “ Bylaws Amendment ”) to the Amended and Restated Bylaws of the Company (the “ Bylaws ”) to include conforming language related to the board declassification in the Company’s Bylaws.”
Anebulo Pharmaceuticals, Inc.: Declassify Board of Directors, directors to stand for election annually (effective 2025-04-11).
“On April 11, 2025, the Company filed the Declassification Charter Amendment with the Secretary of State of the State of Delaware.”
Anebulo Pharmaceuticals, Inc.: Increase authorized common stock from 50M to 75M (effective 2025-04-11).
“On April 11, 2025, the Company filed the Share Increase Amendment with the Secretary of State of the State of Delaware.”
Anebulo Pharmaceuticals, Inc. received a nasdaq extension granted notice regarding shareholders (rules 5635(b)).
“February 24, 2025, the Company received a letter from Nasdaq notifying it that based on the Compliance Plan submitted to Nasdaq, the Nasdaq Staff has determined to grant the Company an extension to regain compliance with Rule 5635(b), as described below. The Compliance Plan proposed that 22NW and the Company enter into an irrevocable lock-up agreement pursuant to which 22NW would agree not to vote, sell, transfer, pledge or otherwise dispose of the Shares until such time as the Company obtained stockholder approval of the removal of such restrictions. In addition, irrevocable instructions to t”
Anebulo Pharmaceuticals, Inc. received a nasdaq deficiency notice notice regarding shareholders (rules 5635(b)).
“February 20, 2025, the Company received a letter (the “Letter”) from The Nasdaq Stock Market (“Nasdaq”) stating that the Company failed to comply with Nasdaq Listing Rule 5635(b) (“Rule 5635(b)”), which requires stockholder approval prior to the issuance of securities when the issuance or potential issuance will result in a change of control of the Company. Prior to the Private Placement, the Company had two directors, Joseph F. Lawler and Aron English, that each beneficially owned in excess of 40% of the Company’s outstanding shares of Common Stock; however immediately after consummation of t”
Anebulo Pharmaceuticals, Inc. reported three months ended March 31, 2024 results: net income Net loss ... was $1.7 million, or $(0.06) per share, EPS $(0.06) per share.
“today announced financial results for the three months ended March 31, 2024”
Anebulo Pharmaceuticals, Inc. reported the three months ended December 31, 2023 results: net income Net loss in the second quarter of fiscal 2024 was $2.7 million, or $(0.11) per share, compared with a net loss of $3.8 m, EPS $(0.11) per share.
“Net loss in the second quarter of fiscal 2024 was $2.7 million, or $(0.11) per share, compared with a net loss of $3.8 million, or $(0.15) per share, in the second quarter of fiscal 2023.”
Anebulo Pharmaceuticals, Inc. shareholders approved Approval of an amendment to our Amended and Restated Certificate of Incorporation to increase the authorized number of shares of common stock from 40,000,000 to 50,000,000. at the 2023-11-20 meeting.
“Proposal No. 3 – Approval of an amendment to our Amended and Restated Certificate of Incorporation to increase the authorized number of shares of common stock from 40,000,000 to 50,000,000.”
Anebulo Pharmaceuticals, Inc. shareholders approved Ratification of the selection by the Audit Committee of the Board of Directors of EisnerAmper LLP as the independent registered public accounting firm of the Company for its fiscal year ending June 30, 2024. at the 2023-11-20 meeting.
“Proposal No. 2 – Ratification of the selection by the Audit Committee of the Board of Directors of EisnerAmper LLP as the independent registered public accounting firm of the Company for its fiscal year ending June 30, 2024.”
Anebulo Pharmaceuticals, Inc. shareholders approved Election of Directors at the 2023-11-20 meeting.
“Proposal No. 1 - Election of Directors The stockholders elected the following two individuals to the Board of Directors to hold office until the 2026 Annual Meeting of Stockholders as Class III directors.”
Anebulo Pharmaceuticals, Inc. reported three months ended September 30, 2023 results: net income $2.5 million, or $(0.10) per share, EPS $(0.10) per share.
“Net loss in the first quarter of fiscal 2024 was $2.5 million, or $(0.10) per share, compared with a net loss of $2.6 million, or $(0.11) per share, in the first quarter of fiscal 2023.”
Bimal Shah was appointed as Director at Anebulo Pharmaceuticals, Inc..
“the Company appointed Bimal Shah as a member of the Board and as a member of the Audit Committee and the Compensation Committee of the Board.”
Richard (Richie) Anthony Cunningham was appointed as Chief Executive Officer at Anebulo Pharmaceuticals, Inc..
“the Board appointed Richard (Richie) Anthony Cunningham as the Company’s Chief Executive Officer and as a member of the Board.”
Simon Allen departed as Chief Executive Officer at Anebulo Pharmaceuticals, Inc..
“On October 6, 2023, Anebulo Pharmaceuticals, Inc., a Delaware corporation (the “Company”), terminated without cause the employment of Simon Allen, the Company’s Chief Executive Officer.”
Sandra A. Gardiner departed as Chief Financial Officer at Anebulo Pharmaceuticals, Inc..
“On September 26, 2023, Anebulo Pharmaceuticals, Inc., a Delaware corporation (the “Company”), appointed Daniel George as the Company’s part-time Chief Financial Officer, as well as the Company’s principal financial officer and principal accounting officer, effective September 28, 2023, replacing Sandra A. Gardiner in such capacities.”
Daniel George was appointed as part-time Chief Financial Officer at Anebulo Pharmaceuticals, Inc..
“On September 26, 2023, Anebulo Pharmaceuticals, Inc., a Delaware corporation (the “Company”), appointed Daniel George as the Company’s part-time Chief Financial Officer, as well as the Company’s principal financial officer and principal accounting officer, effective September 28, 2023, replacing Sandra A. Gardiner in such capacities.”
Anebulo Pharmaceuticals, Inc. reported twelve months ended June 30, 2023 results: net income Net loss in fiscal year 2023 was $11.7 million, or $(0.47) per share, EPS $(0.47) per share.
“Net loss in fiscal year 2023 was $11.7 million, or $(0.47) per share, compared with a net loss of $6.8 million, or $(0.29) per share, in fiscal year 2022.”
Anebulo Pharmaceuticals, Inc. reported three months ended June 30, 2023 results: net income Net loss in the fourth quarter of fiscal 2023 was $2.5 million, or $(0.10) per share, EPS $(0.10) per share.
“Net loss in the fourth quarter of fiscal 2023 was $2.5 million, or $(0.10) per share, compared with a net loss of $2.3 million, or $(0.10) per share, in the fourth quarter of fiscal 2022.”
Anebulo Pharmaceuticals, Inc. terminated Master Services Agreement with Potrero Hill Advisors, LLC valued at Termination of Master Services Agreement effective September 28, 2023 (effective 2023-09-28).
“Item 1.02 Termination of a Material Definitive Agreement. On August 29, 2023, Potrero Hill Advisors, LLC (“Potrero”) provided written notice to terminate that certain Master Services Agreement, dated as of March 2, 2023, by and between Anebulo Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Potrero (the “Master Services Agreement”), effective as of September 28, 2023 (the “Termination Date”).”
Sandra A. Gardiner resigned as Acting Chief Financial Officer at Anebulo Pharmaceuticals, Inc..
“On August 29, 2023, in connection with the termination of the Master Services Agreement, Sandra A. Gardiner notified the Company of her resignation as the Company’s Acting Chief Financial Officer, including as the Company’s principal financial officer and principal accounting officer, effective as of the Termination Date.”
Anebulo Pharmaceuticals, Inc. reported the three months ended March 31, 2023 results: net income $2.8 million, EPS $(0.11) per share.
“Net loss in the third quarter of fiscal 2023 was $2.8 million, or $(0.11) per share, compared with a net loss of $1.9 million, or $(0.08) per share, in the third quarter of fiscal 2022.”
Rex Merchant departed as Chief Financial Officer at Anebulo Pharmaceuticals, Inc..
“replacing Rex Merchant in such capacities.”
Sandra A. Gardiner was appointed as Acting Chief Financial Officer at Anebulo Pharmaceuticals, Inc..
“On March 2, 2023, the Company appointed Sandra A. Gardiner as the Company’s Acting Chief Financial Officer, as well as the Company’s principal financial officer and principal accounting officer, replacing Rex Merchant in such capacities.”
Anebulo Pharmaceuticals, Inc. reported three months ended December 31, 2022 results: net income ($3.8 million), EPS $(0.15).
“Net loss in the second quarter of fiscal 2023 was $3.8 million, or $(0.15) per share, compared with a net loss of $1.1 million, or $(0.05) per share, in the second quarter of fiscal 2022.”
Anebulo Pharmaceuticals, Inc. reported the three months ended September 30, 2022 results: net income $(0.11) per share, EPS $(0.11) per share.
“Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2023 Financial Results and Recent Updates”
Anebulo Pharmaceuticals, Inc. shareholders approved Ratification of the selection by the Audit Committee of the Board of Directors of EisnerAmper LLP as the independent registered public accounting firm of the Company for its fiscal year ending June 30, 2023. at the 2022-10-28 meeting.
“The voting results are as follows: Votes For Votes Against Abstentions Broker Non-Votes 15,992,762 335 1 0”
Anebulo Pharmaceuticals, Inc. shareholders approved Election of Directors at the 2022-10-28 meeting.
“Name Votes For Withheld Broker Non-Votes Nat Calloway 15,985,642 7,456 0 Areta Kupchyk 15,982,304 10,794 0 Kenneth Lin 15,982,304 10,794 0”
Kenneth C. Cundy was appointed as Chief Scientific Officer at Anebulo Pharmaceuticals, Inc..
“On May 24, 2022, Anebulo Pharmaceuticals, Inc. announced that Kenneth C. Cundy has been appointed as the Chief Scientific Officer of our company effective May 20, 2022.”
Daniel Schneeberger resigned as Director at Anebulo Pharmaceuticals, Inc..
“Daniel Schneeberger, M.D. resigned such positions in order to bring in Mr. Allen.”
Daniel Schneeberger resigned as Chief Executive Officer at Anebulo Pharmaceuticals, Inc..
“Daniel Schneeberger, M.D. resigned such positions in order to bring in Mr. Allen.”
Simon Allen was elected as Member of the Board of Directors at Anebulo Pharmaceuticals, Inc..
“On January 3, 2022, Simon Allen was appointed to be our Chief Executive Officer and elected a member of our Board of Directors, both to be effective on February 1, 2022.”
Simon Allen was appointed as Chief Executive Officer at Anebulo Pharmaceuticals, Inc..
“On January 3, 2022, Simon Allen was appointed to be our Chief Executive Officer and elected a member of our Board of Directors, both to be effective on February 1, 2022.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.